Stephan Wehselau

Nascacell Technologies Ag. offers improved, broadened and accelerated modern drug discovery. The company provides services like new generation of biomolecules with its Aptamer and Microbody technologies. Support is given to the customers in the areas of drug discovery and target validation. The company was founded in 2003 and is headquartered in Munich, Germany.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

SpheroTec GmbH develops oncological drug profiling systems. They develop profiling systems that support anti-cancer drug selection programs. Their service areas encompass drug profiling, clinical testing, and diagnostic procedures and functional testing. They engage in projects and partnerships with research institutes, biotechnology and pharmaceutical companies. The company was founded by Barbara Mayer and Ilona Funke on March 20, 2006 and is headquartered in Martinsried, Germany.

Tube Pharmaceuticals GmbH develops a new class of anti cancer drugs. Its products include Tubulysins and their synthetic analogs and next generation Epothilones. The company assets are natural product classes and their synthetic analogues comprising a product platform with multiple partnering and development opportunities. It focuses on synthetic substances for the cancer therapy, derived from natural substances. The company was founded in 2011 and is headquartered in Vienna, Austria.

EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA.

Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.